CBCSG006_2B | R Documentation |
Kaplan-Meier digitized data from CBCSG006, figure 2B (PMID 25795409). A reported sample size of 240 for a primary endpoint of PFS in breast cancer.
CBCSG006_2B
A data frame of 236 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (cis_gemcitabine, paclitaxel_gemcitabine) | |
Hu X-C, Zhang J, Xu B-H, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 436–46.
summary(CBCSG006_2B)
kmplot(CBCSG006_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.